Salvage Chemotherapy
Phase 3Small molecule
Daiichi SankyoSalvage Chemotherapy is one of 104 small molecule programs targeting Lymphoma. It is currently in Phase 3.
4
Indications
6
Total Trials
2
Active Trials
103
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Salvage Chemotherapy
Daiichi SankyoPhase 3
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Relapsed or Refractory2 trials
Acute Myeloid Leukemia1 trial
Lymphoma1 trial
Diffuse Large B-cell Lymphoma(DLBCL)1 trial
An Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07599423·96 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Salvage Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company